KPC-3-Producing *Klebsiella pneumoniae* in Portugal Linked to Previously Circulating Non-CG258 Lineages and Uncommon Genetic Platforms (Tn4401d-IncFIA and Tn4401d-IncN)

Carla Rodrigues 1, Jan Bavlović 2,3, Elisabete Machado 1,4, José Amorim 5, Luísa Peixe 1* and Ângela Novais 1*

1 UCIBIO/REQUIMTE, Laboratório de Microbiologia, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, 2 Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic, 3 Faculty of Military Health Sciences, University of Defense, Brno, Czech Republic, 4 FP-ENAS/CEBIMED, Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal, 5 Botelho Moniz Análises Clínicas, Santo Tirso, Portugal

KPC-3-producing bacteria are endemic in many countries but only recently became apparent their wide distribution in different Portuguese hospitals. The aim of this study is to characterize genetic backgrounds associated with *bla*<sub>KPC</sub>-3 among *Klebsiella pneumoniae* isolates recently identified on non-hospitalized patients in Portugal. Twenty KPC-producing *K. pneumoniae* identified between October 2014 and November 2015 in three different community laboratories were characterized. Isolates were mainly from patients from long-term care facilities (n = 11) or nursing homes (n = 6), most of them (75%) previously hospitalized in different Portuguese hospitals. Standard methods were used for bacterial identification and antibiotic susceptibility testing. Carbapenemase production was assessed by the Blue-Carba test, and identification of *bla* genes was performed by PCR and sequencing. Epidemiological features of KPC-producing *K. pneumoniae* included population structure (*Xba*I-PFGE, MLST and *wzi* sequencing), genetic context (mapping of Tn4401), and plasmid (replicon typing, S1-PFGE, and hybridization) analysis. All *K. pneumoniae* isolates produced KPC-3, with two MDR *K. pneumoniae* epidemic clones representing 75% of the isolates, namely ST147 (*wzi*64/K14.64, February–November 2015) and ST15 (two lineages exhibiting capsular types *wzi*19/K19 or *wzi*93/K60, July-November 2015). Other sporadic clones were detected: ST231 (n = 3; *wzi*104), ST348 (n = 1; *wzi*94) and ST109 (n = 1, *wzi*22/K22.37). *bla*<sub>KPC</sub>-3 was identified within Tn4401 in all isolates, located in most cases (80%) on cointegrated plasmids (rep<sub>FIA</sub> + rep<sub>FI</sub>I + ori<sub>ColE1</sub>; 105-250 kb) or in 50 kb IncN plasmids. In conclusion, this study highlights a polyclonal structure of KPC-3-producing *K. pneumoniae* and the predominance of the ST147 clone among non-hospitalized patients in Portugal, linked to platforms still unnoticed in Europe (*bla*<sub>KPC</sub>-3-Tn4401d-IncFIA) or...
firstly reported \((\text{bla}\text{KPC-3}-\text{Tn4401d-IncN})\). This scenario underlines the recent penetration of successful mobile genetic elements in previously circulating \(K.\ pneumoniae\) lineages (mainly ST147 and ST15) in Portugal, rather than the importation of the global lineages from clonal group 258.

**Keywords:** multidrug resistance, carbapenemases, international clones, ST15, ST147, cointegrated plasmids, ColE

**INTRODUCTION**

In the last years, carbapenem-resistant Enterobacteriaceae have spread globally, being responsible for high rates of morbidity and mortality among healthcare-associated infections, mainly due to the depletion of effective therapeutic options (WHO, 2014; Albiger et al., 2015, http://www.cdc.gov/drugresistance/threat-report-2013/). After the first strain identified in 1996 in a North Carolina hospital (USA; Yigit et al., 2001), Klebsiella pneumoniae carbapenemases (KPCs) have exploded worldwide predominantly among \(K.\ pneumoniae\) isolates (Munoz-Price et al., 2013; Chen et al., 2014b). To date, 23 KPC variants (KPC-2 to KPC-24) have been described (http://www.lahey.org/Studies/other.asp#table1), being KPC-2 and KPC-3 the most widespread variants with variable geographic distribution (Munoz-Price et al., 2013; Nordmann and Poirel, 2014). While in some countries (USA, Colombia, Italy, and Israel) both KPC-2- and KPC-3-producing bacteria are endemic, in others (Argentina, Brazil, Greece, Poland, and China) KPC-2 producers are predominant (Munoz-Price et al., 2013; Albiger et al., 2015).

The \(\text{bla}\text{KPC}\) genes are commonly located on \(\text{Tn4401}\), a 10 kb Tn3-like transposon delimited by two 39-bp imperfect inverted repeat sequences harboring \(\text{bla}\text{KPC}\), transposase and resolvase genes, and insertion sequences \(\text{ISKpn7}\) (upstream \(\text{bla}\text{KPC}\)) and \(\text{ISKpn6}\) (downstream \(\text{bla}\text{KPC}\); Chen et al., 2014b). It is recognized as a highly active transposon enhancing the spread of \(\text{bla}\text{KPC}\) genes to different plasmid scaffolds (Cuzon et al., 2011). To date, six \(\text{Tn4401}\) isoforms have been described with variable deletions between \(\text{ISKpn7}\) and \(\text{bla}\text{KPC}\) providing different promoter regions to the gene \((a, 99 \text{ bp}; b, \text{ no deletion}; c, 215 \text{ bp}; d, 68 \text{ bp}; e, 255 \text{ bp}; g, \text{ equal to isoform } c \text{ but with one single nucleotide mutation on } P2 \text{ promotor})\), and consequently different expression levels of the \(\text{bla}\text{KPC}\) gene (Naas et al., 2012; Chmelnitsky et al., 2014). Besides its genetic environment, other factors are known to have greatly contributed to the spread of KPC producers in many countries, leading to an increasing challenge in the design of effective infection control measures. First, the introduction and subsequent expansion of \(\text{bla}\text{KPC-2}\) and \(\text{bla}\text{KPC-3}\) on multidrug resistant (MDR) \(K.\ pneumoniae\) lineages from clonal group (CG) 258 [sequence types (ST) 11, 258, 512] (Munoz-Price et al., 2013; Chen et al., 2014b), followed in a few countries (e.g., Israel, Italy, Colombia) by subsequent dispersion to other clonal backgrounds (Baraniak et al., 2015; Bonura et al., 2015; Ocampo et al., 2015). Second, the acquisition of \(\text{bla}\text{KPC}\) by plasmids from different incompatibility groups (IncFIK2, IncFIA, IncI2, IncN, IncX3, CoIE), favored a quick intra- and inter-species dissemination (Chen et al., 2014b).

In Portugal, KPC-2 was identified only in an environmental Escherichia coli isolate in 2010 (Poirer et al., 2012), while KPC-3 producers were first detected in 2009 in a central hospital (Machado et al., 2010). However, only recently became evident the widespread distribution of KPC-3 among \(K.\ pneumoniae\) isolates in different Portuguese hospitals (Silva et al., unpublished data; Manageiro et al., 2015). In this study, we aim to trace the landscape of KPC-3-producing \(K.\ pneumoniae\) isolates recently identified outside hospital boundaries in Portugal by detailed characterization of clonal and plasmid genetic backgrounds.

**MATERIALS AND METHODS**

**Bacterial Isolates and Epidemiological Data**

Thirty \(K.\ pneumoniae\) isolates showing reduced susceptibility to carbapenems were identified between October 2014 and November 2015 in three different community laboratories in the North of Portugal, one of them receiving samples from all over the country. Twenty of them were identified as KPC producers and further characterized in this study. They were detected in urine samples \((n = 19)\) or sputum \((n = 1)\) of patients between 61 and 89 years old \((\text{mean age } = 83; 16 \text{ females, } 4 \text{ males}; \text{Table 1})\). Most of these patients were institutionalized in long-term care facilities \((\text{LTCFs})\) \([n = 11; 55\%]\); six different LTCFs \((\text{A–F})\) or nursing homes \((\text{NH})\) \([n = 6; 30\%]; \text{five different NH (A–E)}\), while some were identified in ambulatory \((n = 3; 15\%); \text{Table 1})\). Most of them \((n = 13; 65\%)\) had been hospitalized in the previous month in different hospitals from the North or Centre of Portugal, although in three cases no hospitalization or older hospitalization events \((4–9 \text{ months})\) were detected \((\text{Table 1})\). Travel history abroad was discarded for 60% of the patients \((n = 12/20)\), or considered improbable for the remaining patients due to their clinical conditions \((\text{impaired mobilization and chronic underlying diseases})\).

**Antibiotic Resistance Phenotypes and Genotypes**

Bacterial identification and preliminary antibiotic susceptibility testing were performed by Vitek II system \((\text{BioMérieux, Marcy l’Etoile, France})\). Confirmatory and additional tests for \(\beta\)-lactams \((\text{amoxicillin-clavulanic acid, meccillinam, cefoxitin, extended-spectrum cephalosporins, aztreonam, carbapenems})\), aminoglycosides \((\text{amikacin, gentamicin, netilmicin, tobramycin})\), fluoroquinolones \((\text{ciprofloxacin})\), folate pathway inhibitors \((\text{trimethoprim, trimethoprim-sulfamethaxozole})\), chloramphenicol, fosfomycin, and colistin were assessed by standard disc diffusion \((\text{Oxoid Ltd., Basingstoke, United Kingdom})\).
TABLE 1  Epidemiological data of *K. pneumoniae* isolates carrying *bla*KPC-3-Tn4401d identified in non-hospitalized patients in Portugal (October 2014–November 2015).

| ST (no.) | PFGE-type | Source (no.) | Date of isolation (month/year) | Source of previous hospitalizations (no) | Age (range) | Gender | Sample | Sample Plasmids associated with *bla*KPC-3 (size; Inc groups) (no.) | Other β-lactamases (no.) |
|----------|-----------|--------------|---------------------------------|------------------------------------------|-------------|--------|--------|---------------------------------------------------------------|-------------------------|
| ST147 (10) | w264/K14.64 | LTCF A 2 | Feb–Nov/2015 | unknown | 88–89 | F | Urine | ~130 kb; FIA+FI1+ColE (6) | OXA-9, SHV-28, (TEM-1) |
| ST15 (5) | w264/K14.64 | LTCF A 2 | Jul–Nov/2015 | LTCF A 2 | 83–84 | F | Urine | ~130–140 kb; FIA+FI1+ColE (4) | OXA-9, SHV-28, (TEM-1) |
| ST348 (1) | w264/K14.64 | LTCF A 2 | Sep/2015 | Ambulatory (1) | 88 | F | Urine | ~250 kb; FIA+FI1+ColE (1) | OXA-9, SHV-28, (TEM-1) |
| ST109 (1) | w264/K14.64 | LTCF A 2 | Oct/2015 | NH B (1) | 88 | M | Urine | ~105 kb; FIA+FI1+ColE (1) | OXA-9, SHV-28, (TEM-1) |

**Legend:**
- **ST (no.):** Serotype type (no.)
- **PFGE-type (no.):** PFGE-type (no.)
- **Source (no.):** Source of isolates (no.)
- **Date of isolation (month/year):** Date of isolation (month/year)
- **Source of previous hospitalizations (no):** Source of previous hospitalizations (no)
- **Age (range):** Age (range)
- **Gender:** Gender
- **Sample:** Sample
- **Plasmids associated with *bla*KPC-3 (size; Inc groups) (no.):** Plasmids associated with *bla*KPC-3 (size; Inc groups) (no.)
- **Other β-lactamases (no.):** Other β-lactamases (no.)

*K*-type is reported as per wzi allele-serotype associations reported by Brisse et al. (2013).

LTCFs A–D and NH A–C are located in the North region of Portugal, while LTCFs E–F and NH D–E are located in the Centre region of the country.

Hospitals A, B, and D are located in the North region of Portugal, while Hospitals C, E, F, and G are located in the Centre region of the country.

Older hospitalization events (4–9 months).

No previous hospitalizations in one of the patients.

GenBank accession number KX421191.

LTCF, long-term care facility; NH, nursing home; F, female; M, male.
Kingdom), agar dilution (for fosfomycin; in the presence of glucose-6-phosphate at 25 mg/L), broth microdilution (for colistin) or E-test (for carbapenems) (Liofilchem, Italy) methods according to EUCAST (www.eucast.org).

Production of carbapenemases was assessed by the Blue-Carba test (Pires et al., 2013), and identification of carbapenemases (blaNDM, blaVIM, blaIMP, blaKPC, blaOXA-48) or other bla genes (blaCTX-M, blaSHV, blaTEM, blaOXA) was performed by PCR and sequencing (Curiao et al., 2010; Bogaerts et al., 2013; Rodrigues et al., 2014).

### Population Structure Analysis

Population structure characterization included XbaI-Pulsed-Field Gel Electrophoresis (PFGE) (electrophoresis conditions: 5–20 s for 4 h and 25–50 s for 18 h, 14°C, 6 V/cm²), and multi-locus sequence typing (MLST) (http://biggsdb. web.pasteur.fr/klebsiella/primers_used.html) in representative isolates, as described (Rodrigues et al., 2014). Molecular capsule typing was performed by PCR and sequencing of wzi gene (Brisse et al., 2013).

### Characterization of the Genetic Environment and Location of blaKPC Genes

The genetic context of blaKPC–3 was investigated by PCR and sequencing targeting Tn4401 conserved sequences (Chen et al., 2014a). Location of bla (blaKPC–3, blaCTX–M–15) genes and plasmid characterization were assessed by Sl- and I-CeuI-PFGE and identification of replication genes by PCR, sequencing and hybridization (Carattoli et al., 2005; García-Fernández et al., 2009; Villa et al., 2010; Chen et al., 2014a; Rodrigues et al., 2014).

### RESULTS

#### Carbapenemase Production and Variable Antibiotic Resistance Phenotypes

All isolates produced KPC-3 and demonstrated resistance or intermediate phenotypes to ertapenem (MIC = 1 to 16 mg/L), and susceptible, intermediate or resistance phenotypes to imipenem (MIC = 2 to 16 mg/L) and meropenem (MIC = 1 to 8 mg/L), with colonies growing within the inhibition zone of all carbapenems tested, a hetero-resistance phenotype usually observed for KPC producers (Nordmann et al., 2009; Table 2). Although for some isolates the MIC values for imipenem and meropenem were interpreted as susceptible by the clinical breakpoints defined by EUCAST, in all cases they were above the epidemiological cut-off values (ECOFFs) defined for K. pneumoniae (http://www.eucast.org/mic_distributions_and_ecoff/; Table 2).

All isolates were identified as multidrug resistant (MDR) in accordance with the definition of MDR for Enterobacteriaceae (non-susceptible to ≥1 agent in ≥3 antimicrobial categories; Magiorakos et al., 2012), although some of them exhibited a less extensive resistance profile to non-β-lactams, being resistant only to ciprofloxacin (Table 2). All isolates were susceptible to colistin (MIC = 0.25–2 mg/L; Table 2).

### KPC-3 was Identified Among Locally Circulating K. pneumoniae Clones

KPC-3-producing K. pneumoniae isolates were assigned to six different PFGE-types (arbitrarily designated as Kp1 to Kp6), each one of them linked to a specific capsular type (Table 1). Most isolates belonged to ST147 carrying wzi64 (K14.64; n = 10 Kp1, 50%; detected between February to November 2015) and produced additionally SHV-11 (n = 9) or SHV-28 (n = 1), OXA-9 (n = 6) and/or TEM-1 (n = 1; Table 1). Some (n = 4) of these patients had recently been hospitalized in hospitals (A and D) where KPC-3-producing ST147 isolates exhibiting the same PFGE-type were detected (data not shown, Silva et al., unpublished data). ST15 was also frequent (n = 5, 25%), with two different clones being identified (n = 4 Kp2 carrying wzi19/K19; and n = 1 Kp3 carrying wzi93/K60) between July and November 2015. These isolates co-produced OXA-9 and SHV-28. All ST15-Kp2 were identified in patients from the same LTCF or region, and in one case there was no previous hospitalization (Table 2). ST231 isolates carrying wzi104 (n = 3 Kp4; October 2015) co-produced SHV-1 and TEM-1 (n = 1), and were identified in patients for which no epidemiological link could be established. Sporadic clones such as ST348 carrying wzi94 (n = 1 Kp5; October 2014) or ST109 carrying wzi22 (K22.37; n = 1 Kp6; September 2015) producing other β-lactamases were also detected (Table 1).

### IncFIA and IncN Plasmids Involved in the Dissemination of blaKPC–3-Tn4401d

In all isolates, the blaKPC–3 was identified between ISKpn7 (upstream) and ISKpn6 (downstream), in a structure previously described as Tn4401 isofrom d, known to have a 68bp deletion between ISKpn7 and blaKPC gene (Chen et al., 2014b). Isolates showed a variable number of plasmids (2–5 plasmids) with different sizes (40–500 kb), frequently from IncFIIG and IncR families. In most of the cases (n = 16/20 isolates from different clones), blaKPC–3 was located within cointegrated plasmids (105 to 250 kb) carrying repFIA (100% identity with that of pBK30661 plasmid, GenBank accession number KF954759), repFIA (100% identity with that of pBK30683 plasmid, GenBank accession number KF954760), and oriC_BT (100% identity with ori p15 gene pKBuS13 plasmid, GenBank accession number KM076933). In the remaining isolates (n = 4/20 isolates belonging to ST147), blaKPC–3 was identified in a ca. 50 kb IncN plasmid [repN showing 100% identity with that of pKPC_FCF/35P plasmid (defined by pMLST as repN allele 7; ST15), GenBank accession number CP004367] (Table 1). The two isolates for which a less extended resistance profile was observed (Table 2) carried blaKPC–3 within IncN plasmids and no additional IncF plasmids were observed. The blaCTX–M–15 (when present) was variably located in a ca. 200 kb-IncFIIG (ST348) or in a ca. 60 kb-IncR (ST15-Kp3) plasmid type.

### DISCUSSION

In this study, we highlight a polyclonal structure of KPC-3 producing K. pneumoniae isolates among patients outside...
TABLE 2 | Antimicrobial resistance patterns of KPC-3-producing K. pneumoniae clones.

| Antimicrobial                        | % of Resistance (MIC range, mg/L) | All (n = 20) | ST147 (n = 10) | ST15-Kp2 (n = 4) | ST15-Kp3 (n = 1) | ST231 (n = 3) | ST348 (n = 1) | ST109 (n = 1) |
|--------------------------------------|------------------------------------|--------------|----------------|----------------|-----------------|--------------|--------------|--------------|
| Amoxicillin/clavulanic acid          | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Mecillinam                           | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Ceftazidime                          | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Cefotaxime                           | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Cefepime                             | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Cefotaxime                           | 85                                 | 80           | 100            | 100            | 100             | 100          | 100          | 0            |
| Aztreonam                            | 100                                | 100          | 100            | 100            | 100             | 100          | 100          | 100          |
| Ertapenem                            | 100 (1–16)                         | 100 (1–4)    | 100 (4–16)     | 100 (8)        | 100 (4–8)       | 100 (8)      | 100 (1)      | 100 (1)      |
| Imipenem                             | 75 (2–16)                          | 100 (4–8)    | 25 (2–8)       | 100 (8)        | 33 (2–8)        | 100 (16)     | 100 (4)      | 100 (4)      |
| Meropenem                            | 40 (1–8)                           | 20 (1–4)     | 25 (2–4)       | 100 (8)        | 67 (2–8)        | 100 (4)      | 100 (4)      | 100 (4)      |
| Amikacin                             | 50                                 | 60           | 75             | 0              | 33              | 0            | 0            | 0            |
| Gentamicin                           | 70                                 | 70           | 100            | 0              | 67              | 100          | 0            | 0            |
| Netilmicin                           | 75                                 | 70           | 100            | 100            | 67              | 100          | 0            | 0            |
| Tobramycin                           | 80                                 | 70           | 100            | 100            | 100             | 100          | 0            | 0            |
| Ciprofloxacin                        | 95                                 | 100          | 100            | 100            | 100             | 100          | 0            | 0            |
| Sulfamethoxazole/trimethoprim        | 90                                 | 80           | 100            | 100            | 100             | 100          | 100          | 100          |
| Trimethoprim                         | 90                                 | 80           | 100            | 100            | 100             | 100          | 100          | 100          |
| Chloramphenicol                      | 35                                 | 0            | 75             | 100            | 100             | 100          | 0            | 0            |
| Fosfomycin                           | 15                                 | 10           | 0              | 100            | 0               | 100          | 0            | 0            |
| Colistin                             | 0                                  | 0            | 0              | 0              | 0               | 0            | 0            | 0            |

*aAll intermediate isolates were considered as resistant.
*bClinical Breakpoints (Ertapenem - S \( \leq 0.5 \) mg/L; Imipenem and Meropenem - S \( \leq 2 \) mg/L) and ECOFF values (Ertapenem - WT \( \leq 0.064 \) mg/L; Imipenem - WT \( \leq 1 \) mg/L; Meropenem - WT \( \leq 0.125 \) mg/L) for MIC defined by EUCAST for K. pneumoniae.

hospital boundaries in Portugal consistent with nosocomial acquisition, and unveil novel or uncovered plasmid backbones carrying bla\text{KPC-3} in Europe.

The first clinical cases of KPC-3 producers in Portugal were detected in 2009 in a pediatric unit of a hospital from the Lisbon and Tagus Valley region and involved 2 K. pneumoniae belonging to ST11 (Machado et al., 2010). Months later and until 2011, an outbreak involving 41 KPC-3-producing isolates, most of them (n = 29) assigned to ST14, was reported (Calisto et al., 2012). More recently, a nationwide study reported 22 K. pneumoniae producing KPC-3 (mainly ST11, ST14, ST15, and ST147 clones) in several hospitals between 2010 and 2013 but plasmid backgrounds had been poorly characterized (Manageiro et al., 2015). However, the situation concerning carbapenemase-producing Enterobacteriaceae in Portugal was only recently recognized in the EuSCAPE survey, where our country appeared in level 2b (sporadic hospital outbreaks) mainly due to the expansion of KPC producers (Albiger et al., 2015). These “high-risk clones” have been linked to the worldwide expansion of different ESBL (CTX-M-15 and different SHV-types) and carbapenemases (KPC, VIM, NDM, OXA-48-like), including in Portugal (Rodrigues et al., 2014). This scenario suggests recent acquisition of bla\text{KPC-3} by MDR K. pneumoniae genetic lineages that were already circulating in Portugal (ST15, ST147, ST231, ST348), a situation observed less frequently than the amplification of CG258 lineages (Baraniak et al., 2015; Bonura et al., 2015; Ocampo et al., 2015).

The ST147 clone [clonal group (CG) 147] exhibiting capsular type K14.K64 was identified in patients from diverse LTCFs and NHs for a long period of time and seems to be the predominant lineage among KPC-3-producing K. pneumoniae in different
healthcare settings (Silva et al., unpublished data; Manageiro et al., 2015). In fact, identical KPC-3-producing ST147 isolates were recently involved in outbreaks in hospitals where some of the patients had been previously hospitalized. Although, nosocomial acquisition is the most probable origin for most KPC-3 producers identified in patients included in this study, it is of notice that in three cases no obvious hospitalization link could be established. Indeed, considering the frequent displacement of these patients between institutions (integrated network of LTCFs in Portugal) and hospitals (we had only access to the last hospitalization event) and that intestinal colonization might be persistent in time (Feldman et al., 2013), we cannot completely discard cross transmission events in the units analyzed.

The identification of two distinct ST15 (CG15) lineages in this study (ST15-K19 and ST15-K60) is in line with recent studies based on wzi-capsule typing unveiling the circulation of distinct lineages within this CG, that might have differences in their relative occurrence, geographical, or niche distribution and/or host susceptibility (Bialek-Davenet et al., 2014; Holt et al., 2015; Rodrigues et al., 2015; Zhou et al., 2015, http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html). The ST231 K. pneumoniae clone (CG231) had already been linked to GES-5 plus SHV-12 production in Portugal (Manageiro et al., 2015) and its association with community invasive infections (sepsis, lethal pneumonia, or meningitis), and high content in virulence and antimicrobial resistance genes have recently been highlighted (Holt et al., 2015). The ST109 clone is rarely reported (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html) and it is described for the first time in Portugal. However, it belongs to the CG17, associated with the expansion of CTX-M-15 and different carbapenemases worldwide (Rodrigues et al., 2014; Holt et al., 2015).

The blakPC−3 was linked to Tn4401d isoform in all characterized KPC-3-producing Enterobacteriaceae from Portugal (this study; Manageiro et al., 2015). In this study, we show that in most cases (80%) Tn4401d-blakPC−3 was located within cointegrated FIA, FII, and ColE1 plasmids (105−250 kb; Table 1) corroborating the strong association between Tn4401d-blakPC−3 with IncFIA plasmids pointed out previously in large collections from the USA (Chen et al., 2014a; Deleo et al., 2014; Bowers et al., 2015; Chavda et al., 2015). We detected FIA and FII replicas to those of pBK30683 plasmid (GenBank accession number KP954760) plus an additional oriColE1 gene identical to that of the ColE1 plasmid pKBU13 (GenBank accession number KM076933), supporting the role of these mobilizable plasmids in the assembly of MDR plasmids (Chen et al., 2014a; Garbari et al., 2015). These and other (IncFIA plus IncA/C2 or IncFIA plus IncX3) cointegration forms seem to play an important role in the intra- and inter-species spread of carbapenem resistance genes (Chen et al., 2014a,b; Chavda et al., 2015). To the best of our knowledge, we unveil for the first time a cointegrate IncFIA platform carrying Tn4401d-blakPC−3 in Europe, characterized and highly represented by far only in isolates from the USA (mainly among non-ST258 and non-K. pneumoniae isolates; Chen et al., 2014a). In the remaining isolates (20%, 4 ST147), blakPC−3-Tn4401d was located on ca. 50 kb IncN plasmids, an association primarily described in this study.

In conclusion, this study highlights a polyclonal structure among KPC-3 producers identified in geographically dispersed non-hospitalized patients in Portugal, not always linked to nosocomial acquisition, a situation that deserves close monitoring due to its high clinical or epidemiological impact. In all cases, a common platform (blakPC−3-Tn4401d) was identified in plasmids still unnoticed in Europe (blakPC−3-IncFIA) or firstly reported here (blakPC−3-Tn4401d-IncN). Their identification in previously circulating MDR K. pneumoniae lineages in our area (ST147, ST15, ST231, ST348) underlines the recent penetration of successful mobile genetic elements in locally circulating clonal backgrounds, rather than the importation of the most common global lineages from CG258.

AUTHOR CONTRIBUTIONS

CR and JB performed the experiments and contributed with the acquisition of molecular data. CR and ÂN wrote the article and performed analysis and interpretation of molecular data. EM and JA contributed with epidemiological data and revision of the manuscript. ÂN and LP contributed with the design of the study and final revision of the manuscript. All authors read and approved the final version of the manuscript.

FUNDING

This work received financial support from the European Union (FEDER funds) through Programa Operacional Factores de Competitividade – COMPETE and National Funds (FCT, Fundação para a Ciência e Tecnologia) (UID/Multi/04378/2013). ÂN and CR were supported by fellowships (grant number SFRH/BPD/104927/2014 and SFRH/BD/84341/2012, respectively) from FCT through Programa Operacional Capital Humano (POCH).

ACKNOWLEDGMENTS

We thank Dr. Carlos Mendes, Dr. Alexandra Gomes, and Dr. Bibiana Marques (Laboratório de Análises Clínicas Doutor Carlos Torres), Dr. Rui Campainha and Dr. Sofia Moniz (Botelho Moniz Análises Clínicas - BMAC), and Dr. Ricardo Silva (Santa Casa da Misericórdia, Vila do Conde) for providing the strains and the clinical/epidemiological data included in this study.
REFERENCES

Albiguer, B., Glaser, C., Struelens, M. J., Grundmann, H., Monnet, D. L. and European Survey of Carbenapenem-Producing Enterobacteriaceae (EuSCAPE) working group (2015). Carbenapenem-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries. May 2015. Euro Surveill. 20:30062. doi: 10.2807/1560-7917.ES.2015.20.45.30062

Bariani, A., Izdebki, R., Pfeif, J., Herda, M., Derde, L. P. G., Bonten, M. J. M., et al. (2015). KPC-like carbapenem-producing Enterobacteriaceae colonizing patients in Europe and Israel. Antimicrob. Agents Chemother. 60, 1912–1917. doi: 10.1128/AAC.02756-15

Bialek-Davenet, S., Criscuolo, A., Ailourd, F., Passet, V., Jones, L., Delannoy-Viellard, A.-S., et al. (2014). Genomic definition of hypervirulent and multidrug-resistant Klebsiella pneumoniae clonal groups. Emerg. Infect. Dis. 20, 1812–1820. doi: 10.3203/eid2011.140206

Bogaerts, P., Rezende de Castro, R., de Mendonça, R., Huang, T.-D., Denis, O., and Glupczynski, Y. (2013). Validation of carbapenemase and extended-spectrum β-lactamase multiplex endpoint PCR assays according to ISO 15189. J. Antimicrob. Chemother. 68, 1576–1582. doi: 10.1093/jac/dkt065

Bonura, C., Giuffre, M., Aleo, A., Fasciana, T., Di Bernardo, F., Stampone, T., et al. (2015). An update of the evolving epidemic of blaKPC carrying Klebsiella pneumoniae in Sicily, Italy, 2014: emergence of multiple Non-ST258 clones. PLoS ONE 10:e0132936. doi: 10.1371/journal.pone.0132936

Bowers, J. R., Kitchel, B., Driebe, E. M., MacCannell, D. R., Roe, C., Lemmer, C., et al. (2011). Functional characterization of qnrB19 genes in Klebsiella pneumoniae multidrug-resistant strains. J. Antimicrob. Chemother. 68, 1576–1582. doi: 10.1093/jac/dkt065

Chen, L., Chavda, K. D., Melano, R. G., Hong, T., Rojtman, A. D., Jacobs, M. R., et al. (2014). Molecular dissection of the evolution of carbapenem-resistant Klebsiella pneumoniae multilocus sequence type 258 Klebsiella pneumoniae. Proc. Natl. Acad. Sci. U.S.A. 111, 4988–4993. doi: 10.1073/pnas.1321364111

Feldman, N., Adler, A., Molshatzki, N.,Navon-Venezia, S., Khabrav, E., Cohen, D., et al. (2013). Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriage. Clin. Microbiol. Infect. 19, E190–E196. doi: 10.1111/1469-0691.12099

Garbari, L., Busetti, M., Dolzani, L., Petix, V., Knezevich, A., Bressan, R., et al. (2015). pKbSuS1, a KPC-2-encoding plasmid from Klebsiella pneumoniae sequence type 833, carrying Tn4401b inserted into an Xer site-specific recombination locus. Antimicrob. Agents Chemother. 59, 5226–5321. doi: 10.1128/AAC.04534-14

García-Fernández, A., Fortini, D., Veldman, K., Mevius, D., and Carattoli, A. (2009). Characterization of plasmids harbouring qnrS1, qnrB2 and qnrB19 genes in Salmonella. J. Antimicrob. Chemother. 63, 274–281. doi: 10.1093/jac/dkn470

Holt, K. E., Wertheim, H., Zadoks, R. N., Baker, S., Whitehouse, C. A., Dance, D., et al. (2015). Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. U.S.A. 112, E3574–E3581. doi: 10.1073/pnas.15049112

Klebsiella pneumoniae
Villa, L., García-Fernández, A., Fortini, D., and Carattoli, A. (2010). Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. *J. Antimicrob. Chemother.* 65, 2518–2529. doi: 10.1093/jac/dkq347

WHO (2014). *Antimicrobial Resistance: Global Report on Surveillance.* Geneva: WHO Press, World Health Organization.

Yigit, H., Queenan, A. M., Anderson, G. I., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., et al. (2001). Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 45, 1151–1161. doi: 10.1128/AAC.45.4.1151-1161.2001

Zhou, K., Lokate, M., Deurenberg, R. H., Tepper, M., Arends, J. P., Raangs, E. G. C., et al. (2015). Use of whole-genome sequencing to trace, control and characterize the regional expansion of extended-spectrum β-lactamase producing ST15 *Klebsiella pneumoniae*. *Sci Rep.* 11:6:20840. doi: 10.1038/srep20840

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Rodrigues, Bavlović, Machado, Amorim, Peixe and Novais. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.